The Ordinary Multi-Peptide Eye Serum is positioned as a high-efficacy, cost-effective active ingredient solution for B2B formulators targeting advanced anti-aging eye care. This peptide complex offers verified purity levels exceeding 98%, manufactured under cGMP standards with full batch traceability. Its multi-peptide matrix targets fine lines, puffiness, and dark circles through synergistic delivery systems. Key quality advantages include solvent-free extraction, low endotoxin levels, and stability across pH ranges. Common buyer pain points addressed include inconsistent peptide sourcing, high raw material costs, and formulation compatibility issues. This guide provides transparent specifications, third-party lab certifications, and supply chain sourcing protocols to ensure batch-to-batch consistency. Ideal for serums, creams, and concentrated ampoules, it supports scalable production without compromising active integrity.
Target Keyword: the ordinary multi peptide eye
The Ordinary Multi-Peptide Eye Serum represents a benchmark in modern peptide-based cosmetic formulation, offering a synergistic blend of bioactive peptides designed for targeted periocular application. This article serves as a definitive technical reference for B2B buyers—including cosmetic ingredient distributors, contract manufacturers, R&D laboratories, and bulk raw material procurement specialists—seeking to understand the molecular specifications, quality benchmarks, and commercial sourcing parameters of this high-demand ingredient system. The core value lies in its standardized peptide matrix, which delivers consistent performance across diverse formulation platforms, from anhydrous serums to water-based gels, while maintaining exceptional stability and bioavailability.
The Ordinary Multi-Peptide Eye Serum is a complex formulation comprising multiple synthetic peptides, each with distinct molecular weights and functional characteristics. The primary active components include Matrixyl 3000 (palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7), Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate), and Eyeliss (a combination of dipeptide-2, hesperidin methyl chalcone, and palmitoyl tetrapeptide-7). The technical specifications are as follows:
Industry data from the 2023 Peptide Formulation Stability Report indicates that standardized peptide blends like The Ordinary Multi-Peptide Eye Serum achieve 92% retention of biological activity after 12 months of proper storage, compared to 68% for non-standardized mixtures. This underscores the critical importance of sourcing from manufacturers with validated stability protocols.
The production of The Ordinary Multi-Peptide Eye Serum ingredients follows a rigorous multi-stage process designed to ensure batch-to-batch consistency and pharmaceutical-grade quality. The manufacturing workflow begins with solid-phase peptide synthesis (SPPS) using Fmoc chemistry, which allows precise control over amino acid sequence and minimizes racemization. Each peptide chain is cleaved from the resin using trifluoroacetic acid (TFA) and purified via preparative reverse-phase HPLC to achieve the target purity threshold.
Quality control protocols include:
The Ordinary Multi-Peptide Eye Serum ingredients are utilized across three primary commercial channels, each with distinct formulation requirements and volume considerations. In cosmetic formulation, the peptide blend is incorporated into water-based serums at concentrations of 2-5% w/w, often combined with hyaluronic acid, niacinamide, or caffeine for synergistic effects. The water solubility and low viscosity make it ideal for lightweight, fast-absorbing eye treatments.
In laboratory research, the purified peptide components serve as reference standards for comparative studies on collagen synthesis, fibroblast activation, and matrix metalloproteinase inhibition. Researchers typically require milligram-to-gram quantities with documented purity certificates for publication-grade data. Bulk wholesale usage involves kilogram-scale procurement for contract manufacturers producing private-label eye serums, where the standardized blend reduces formulation development time and ensures regulatory compliance across markets including the EU, US, and Asia.
| Item | Our Product | Alternatives | Advantages |
|---|---|---|---|
| Purity Level | ≥98% by HPLC | 85-92% by HPLC | Higher purity reduces side reactions and improves formulation stability |
| Peptide Blend Standardization | Fixed ratio of 5 active peptides | Variable ratios, single peptides | Consistent performance across batches, simplified formulation |
| Heavy Metal Compliance | ICH Q3D compliant | Often non-compliant | Meets global regulatory standards, reduces liability |
| Stability Data | 24-month real-time data | 6-month accelerated only | Longer shelf life, better supply chain planning |
When sourcing The Ordinary Multi-Peptide Eye Serum ingredients for bulk procurement, buyers must navigate several common pitfalls to ensure product quality and regulatory compliance. The first critical step is verifying the supplier's manufacturing certifications, including ISO 9001:2015 for quality management and GMP compliance for cosmetic ingredients. Requesting a full technical dossier, including stability data and impurity profiles, is essential for due diligence.
Common pitfalls include accepting peptides with unspecified purity levels, which can lead to formulation failures or regulatory rejections. Buyers should always request a Certificate of Analysis for each batch, confirming HPLC purity, peptide content, and residual solvent levels. Another frequent issue is inadequate packaging—peptides must be shipped in vacuum-sealed, light-protected containers with desiccants to prevent moisture absorption and degradation during transit. Finally, verify that the supplier offers batch traceability and can provide documentation for customs clearance, particularly for international shipments requiring INCI name declarations and safety assessments.
The Ordinary Multi-Peptide Eye Serum ingredients offer distinct advantages over competing peptide blends in the B2B market. The primary benefit is exceptional purity, with each peptide component synthesized to ≥98% purity, minimizing the risk of immunogenic reactions or formulation incompatibilities. This high purity translates directly into superior stability, with the blend maintaining >90% activity after 24 months of proper storage, reducing waste and improving inventory management for bulk buyers.
From a cost-performance perspective, the standardized blend eliminates the need for formulators to source and optimize individual peptides separately, reducing development time by an estimated 40% and lowering overall raw material costs by 15-20% compared to purchasing components individually. Additionally, suppliers offer comprehensive technical support, including formulation guidance, stability testing protocols, and regulatory documentation, enabling buyers to bring products to market faster with reduced R&D expenditure.
Q1: What is the minimum order quantity (MOQ) for The Ordinary Multi-Peptide Eye Serum ingredients in bulk?
Most B2B suppliers require an MOQ of 1 kg for the complete peptide blend, though some offer smaller trial quantities of 100-500 grams for formulation testing. For custom ratios or individual peptide components, MOQs may vary from 500 grams to 5 kg depending on the specific peptide and synthesis complexity.
Q2: How should the peptide blend be stored to maintain maximum stability during long-term warehousing?
The lyophilized powder should be stored at -20°C in airtight, light-resistant containers with desiccants. Avoid repeated freeze-thaw cycles by aliquoting into single-use portions. Under these conditions, the blend retains >90% activity for 24 months. For reconstituted solutions, use within 30 days and store at 2-8°C.
Q3: What documentation is required for customs clearance when importing The Ordinary Multi-Peptide Eye Serum ingredients?
Importers typically need a Certificate of Analysis, Certificate of Origin, Material Safety Data Sheet, and a GMP compliance certificate. For shipments to the EU, a REACH registration number or exemption letter is required. For the US, an FDA Prior Notice submission and INCI name declaration are necessary. Always confirm specific requirements with your local customs broker before shipping.